Signals, Powered By EquityPandit
Suven Life Science has got product patents from Israel, Macau and South Korea for New Chemical Entities (NCEs) that are used in treating disorders associated with neurodegenerative diseases.
The company has said in a statement that these patents are valid through 2032.
Venkat Jasti, Suven CEO has said “We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally.”
